Submit RFP

While recurrence free survival is the accepted surrogate endpoint for oncology, biomarker-based outcomes assessment with ctDNA may offer greater precision and sensitivity. What could acceptance of biomarker-based surroga...

What would make you return to a former employer? After more than a decade building his career across pharma and CROs, Albert Bekfi returned to ICON as Vice President, Pharmacovigilance and Safety Reporting, Service Deli...

Winning Best Clinical Trial Supplier: Site Innovation at ABEA 2026 is a testament to the outstanding collaboration, expertise and commitment of ICON’s APAC teams. We thank IMAPAC for recognising innovation that ultimate...

Tissue‑based screening workflows create weeks‑long delays and site burden; shifting screening infrastructure toward blood‑based ctDNA assays may identify eligible patients within days while preserving analytic rigor. Exp...

What will it take to translate ambition into measurable progress in clinical trial representation? Tinaya Gray, Executive Director of ICON Site Engagement & PACE, joined ACRO’s Good Clinical Podcast to discuss how the i...

We’re excited to be part of #SCDMChina this year, taking place from 3 - 4 July in Shanghai. Visit booth \#6 tomorrow to meet our team and learn how ICON is revolutionising clinical research with cutting-edge data-driven ...

Oligonucleotide (ON) drug development is accelerating rapidly—but first‑in‑human (FIH) studies remain complex. Listen to our recent webinar where specialists discussed: - Translational PK/PD and toxicity considerations ...

The recent implementation of ICH Q5A(R2) marks the most consequential shift in viral safety for biotechnology products since the 1990s, moving sponsors toward risk based, technology enabled controls that can shorten test...

Many molecularly guided treatments with tumor-agnostic potential are still modulated by lineage-specific biology. Emerging tools that predict whether a molecular target is appropriate for tumor-agnostic development could...

Global trends for drug-device combination product regulation are moving toward an integrated approach, shifting away from quality systems that prioritise just one component of the combination. From integrated quality sy...

How will the latest regulatory changes impact your biosimilar strategy? The March 2026 updates from the EMA and FDA are redefining expectations — from reduced reliance on comparative efficacy studies to more streamlined...

The shift towards real-time clinical trials could reduce long-standing inefficiencies in data flow and accelerate early decision-making. However, greater transparency also introduces new challenges in governance, data ma...